{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:57Z","timestamp":1794047517396,"version":"4.8.0"},"reference-count":70,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Exciting therapeutic advances are transforming the mantle cell lymphoma (MCL) treatment landscape, with an expanding array of novel agents. Growing evidence demonstrates that MCL is a biologically heterogeneous disease ineffectively managed with historical uniform standard chemoimmunotherapy approaches. Furthermore, traditional prognosticators such as the MCL-International Prognostic index (MIPI), proliferation index Ki-67, and presence of TP53 aberrations remain valuable but are insufficient to fully capture disease complexity or guide personalized therapy. Biomarker technologies are evolving rapidly. Reflecting this technological renaissance, recent studies have identified a range of novel molecular and cytogenetic alterations that carry prognostic or therapeutic relevance in the context of both chemotherapy and novel agent delivery. Advances in measurable residual disease detection using polymerase chain reaction analysis, next-generation sequencing, and circulating tumor DNA are reshaping risk stratification and offer the potential to guide therapy intensity and duration. New information is emerging regarding the critical role of the tumor microenvironment and immune dysregulation in driving treatment resistance. Additionally, the expanding utility of fluorodeoxyglucose positron emission tomography by harnessing quantitative parameters and radiomic data offers new opportunities for multimodality risk stratification. Here, we comprehensively review the literature beyond established MCL prognosticators and provide an overview of these newer prognostic and predictive biomarkers for MCL in modern treatment paradigms, and their role in informing treatment decisions and future research directions.<\/jats:p>","DOI":"10.3324\/haematol.2025.288185","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:34:07Z","timestamp":1762418047000},"page":"1198-1214","source":"Crossref","is-referenced-by-count":5,"title":["Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies"],"prefix":"10.3324","volume":"111","author":[{"given":"Zoe","family":"Loh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"87406","doi-asserted-by":"crossref","unstructured":"Hoster E, Dreyling M, Klapper W. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(2):558-565.","DOI":"10.1182\/blood-2007-06-095331"},{"key":"87407","doi-asserted-by":"crossref","unstructured":"Hoster E, Rosenwald A, Berger F. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-1394.","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"87408","doi-asserted-by":"crossref","unstructured":"Gin\u00e9 E, de la Cruz F, Jim\u00e9nez Ubieto A. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022; 40(11):1196-1205.","DOI":"10.1200\/JCO.21.02321"},{"key":"87409","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Jerkeman M. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022; 386(26):2482-2494.","DOI":"10.1056\/NEJMoa2201817"},{"key":"87410","doi-asserted-by":"crossref","unstructured":"Wang ML, Jain P, Zhao S. Ibrutinib\u2013rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022; 23(3):406-415.","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"87411","doi-asserted-by":"crossref","unstructured":"Kumar A, Soumerai J, Abramson JS. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025; 145(5):497-507.","DOI":"10.1182\/blood.2024025563"},{"key":"87412","doi-asserted-by":"crossref","unstructured":"Ruan J, Bond DA, Shah BD. MRD-driven time-limited therapy of acalabrutinib and lenalidomide plus rituximab (ALR) or obinutuzumab (ALO) in patients with treatment-na\u00efve mantle cell lymphoma: phase 2 trial outcomes with MRD and cfDNA analyses. Blood. 2024; 144(Supplement 1):746.","DOI":"10.1182\/blood-2024-204495"},{"key":"87413","doi-asserted-by":"crossref","unstructured":"Epperla N, Switchenko JM, Geyer SM. Ki-67 expression of 50% Is the optimal cut-off to predict survival outcomes in mantle cell lymphoma (MCL): a pooled analysis from CALGB 50403 (Alliance) and MCL real-world study cohort. Blood. 2023; 142(Supplement 1):380.","DOI":"10.1182\/blood-2023-189505"},{"key":"87414","doi-asserted-by":"crossref","unstructured":"Gerson JN, Handorf E, Villa D. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023; 7(24):7393-7401.","DOI":"10.1182\/bloodadvances.2023010757"},{"key":"87415","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling M, Goy A. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017; 179(3):430-438.","DOI":"10.1111\/bjh.14870"},{"key":"87416","doi-asserted-by":"crossref","unstructured":"Bond DA, Switchenko JM, Villa D. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021; 5(23):5179-5189.","DOI":"10.1182\/bloodadvances.2021004765"},{"key":"87417","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Chartier L, Ribrag V. Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study. Blood Cancer J. 2025; 15(1):78.","DOI":"10.1038\/s41408-025-01241-9"},{"key":"87418","doi-asserted-by":"crossref","unstructured":"He Y, Wang C, Pan T. POD24-based prognostic signature enables personalized risk stratification in mantle cell lymphoma. Sci Rep. 2025; 15(1):8687.","DOI":"10.1038\/s41598-025-92963-0"},{"key":"87419","doi-asserted-by":"crossref","unstructured":"Albano D, Treglia G, Gazzilli M, Cerudelli E, Giubbini R, Bertagna F. 18F-FDG PET or PET\/CT in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2020; 20(7):422-430.","DOI":"10.1016\/j.clml.2020.01.018"},{"key":"87420","doi-asserted-by":"crossref","unstructured":"Albano D, Bianchetti N, Talin A. Prognostic role of pretreatment tumor burden and dissemination features from 2-[18F]FDG PET\/CT in advanced mantle cell lymphoma. Hematol Oncol. 2025; 43(1):e70009.","DOI":"10.1002\/hon.70009"},{"key":"87421","doi-asserted-by":"crossref","unstructured":"Mayerhoefer ME, Riedl CC, Kumar A. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging. 2019; 46(13):2760-2769.","DOI":"10.1007\/s00259-019-04420-6"},{"key":"87422","doi-asserted-by":"crossref","unstructured":"Liu F, Gu B, Li N. Prognostic value of heterogeneity index derived from baseline 18F-FDG PET\/CT in mantle cell lymphoma. Front Oncol. 2022; 12:862473.","DOI":"10.3389\/fonc.2022.862473"},{"key":"87423","doi-asserted-by":"crossref","unstructured":"Greenwell IB, Staton AD, Lee MJ. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018; 124(11):2306-2315.","DOI":"10.1002\/cncr.31328"},{"key":"87424","doi-asserted-by":"crossref","unstructured":"Malarikova D, Berkova A, Obr A. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers (Basel). 2020; 12(8):2120.","DOI":"10.3390\/cancers12082120"},{"key":"87425","doi-asserted-by":"crossref","unstructured":"Nadeu F, Martin-Garcia D, Clot G. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020; 136(12):1419-1432.","DOI":"10.1182\/blood.2020005289"},{"key":"87426","doi-asserted-by":"crossref","unstructured":"Jain P, Tang G, Yin CC. Complex karyotype is a significant predictor for worst outcomes in patients with mantle cell lymphoma (MCL) treated with BTK inhibitors - comprehensive analysis of 396 patients. Blood. 2020; 136(Supplement 1):32-33.","DOI":"10.1182\/blood-2020-137473"},{"key":"87427","doi-asserted-by":"crossref","unstructured":"Le Bris Y, Magrangeas F, Moreau A. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. Hematol Oncol. 2020; 38(4):446-455.","DOI":"10.1002\/hon.2750"},{"key":"87428","doi-asserted-by":"crossref","unstructured":"Hill HA, Qi X, Jain P. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020; 4(13):2927-2938.","DOI":"10.1182\/bloodadvances.2019001350"},{"key":"87429","doi-asserted-by":"crossref","unstructured":"Delfau-Larue M-H, Klapper W, Berger F. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015; 126(5):604-611.","DOI":"10.1182\/blood-2015-02-628792"},{"key":"87430","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Dahl C, Hansen JW. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17):1903-1910.","DOI":"10.1182\/blood-2017-04-779736"},{"key":"87431","doi-asserted-by":"crossref","unstructured":"Obr A, Klener P, Furst T. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol. 2020; 191(5):e103-e106.","DOI":"10.1111\/bjh.17063"},{"key":"87432","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Hassan M, Freiburghaus C. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol. 2020; 191(5):796-805.","DOI":"10.1111\/bjh.17023"},{"key":"87433","doi-asserted-by":"crossref","unstructured":"Aukema SM, Hoster E, Rosenwald A. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018; 131(4):417-420.","DOI":"10.1182\/blood-2017-07-797019"},{"key":"87434","doi-asserted-by":"crossref","unstructured":"Wang M, Jurczak W, Trneny M. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025; 26(2):200-213.","DOI":"10.1016\/S1470-2045(24)00682-X"},{"key":"87435","doi-asserted-by":"crossref","unstructured":"Epstein-Peterson ZD, Drill E, Aypar U. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation. Haematologica. 2024; 109(4):1149-1162.","DOI":"10.3324\/haematol.2024.285845"},{"key":"87436","doi-asserted-by":"crossref","unstructured":"Wang Y, Jain P, Locke FL. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41(14):2594-2606.","DOI":"10.1200\/JCO.22.01797"},{"key":"87437","doi-asserted-by":"crossref","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study. J Clin Oncol. 2025; 43(3):318-328.","DOI":"10.1200\/JCO.23.02470"},{"key":"87438","doi-asserted-by":"crossref","unstructured":"Rahal R, Frick M, Romero R. Pharmacological and genomic profiling identifies NF-kB\u2013targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014; 20(1):87-92.","DOI":"10.1038\/nm.3435"},{"key":"87439","doi-asserted-by":"crossref","unstructured":"Wu C, de Miranda NF, Chen L. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016; 7(25):38180-38190.","DOI":"10.18632\/oncotarget.9500"},{"key":"87440","doi-asserted-by":"crossref","unstructured":"Decombis S, Bellanger C, Le Bris Y. CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 2023; 142(18):1543-1555.","DOI":"10.1182\/blood.2023020211"},{"key":"87441","doi-asserted-by":"crossref","unstructured":"Song Y, Zhou K, Zou D. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139(21):3148-3158.","DOI":"10.1182\/blood.2021014162"},{"key":"87442","doi-asserted-by":"crossref","unstructured":"Freeman CL, Pararajalingam P, Jin L. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022; 36(10):2479-2487.","DOI":"10.1038\/s41375-022-01658-2"},{"key":"87443","doi-asserted-by":"crossref","unstructured":"Agarwal R, Chan Y-C, Tam CS. Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019; 25(1):119-129.","DOI":"10.1038\/s41591-018-0243-z"},{"key":"87444","doi-asserted-by":"crossref","unstructured":"Scott DW, Abrisqueta P, Wright GW. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017; 35(15):1668-1677.","DOI":"10.1200\/JCO.2016.70.7901"},{"key":"87445","doi-asserted-by":"crossref","unstructured":"Freeman CL, Srinivasan S, Hodkinson B. Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status. Blood. 2025; 145(25):3052-3056.","DOI":"10.1182\/blood.2024026003"},{"key":"87446","unstructured":"Yi S, Yan Y, Jin M. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. 2025."},{"key":"87447","doi-asserted-by":"crossref","unstructured":"Wang ML, Jain P, Zhao S. Ibrutinib\u2013rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022; 23(3):406-415.","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"87448","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Hollander P, Schmidt L. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53\/p53 \u2013 a Nordic Lymphoma Group study. Haematologica. 2024; 109(4):1171-1183.","DOI":"10.3324\/haematol.2023.283352"},{"key":"87449","doi-asserted-by":"crossref","unstructured":"Dahl M, Husby S, Eskelund CW. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2022; 36(1):177-188.","DOI":"10.1038\/s41375-021-01311-4"},{"key":"87450","doi-asserted-by":"crossref","unstructured":"Salim R, Eskelund CW, Jerkeman M. Exploring the prognostic potential of circSCORE in patients with relapsed\/ refractory mantle cell lymphoma. Genes (Basel). 2025; 16(6):634.","DOI":"10.3390\/genes16060634"},{"key":"87451","doi-asserted-by":"crossref","unstructured":"He J, Xi Y, Gao N, Xu E, Chang J, Liu J. Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma. J Int Med Res. 2021; 49(5):03000605211016390.","DOI":"10.1177\/03000605211016390"},{"key":"87452","doi-asserted-by":"crossref","unstructured":"Assis-Mendon\u00e7a GR, Fattori A, Rocha RM. Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma. BMC Cancer. 2021; 21(1):209.","DOI":"10.1186\/s12885-021-07891-9"},{"key":"87453","doi-asserted-by":"crossref","unstructured":"Balsas P, Veloza L, Clot G. SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021; 138(22):2202-2215.","DOI":"10.1182\/blood.2020010527"},{"key":"87454","doi-asserted-by":"crossref","unstructured":"Jain P, Nomie K, Kotlov N. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023; 13(1):156.","DOI":"10.1038\/s41408-023-00927-2"},{"key":"87455","doi-asserted-by":"crossref","unstructured":"Nygren L, Wasik AM, Baumgartner-Wennerholm S. T-cell levels are prognostic in mantle cell lymphoma. Clin Cancer Res. 2014; 20(23):6096-6104.","DOI":"10.1158\/1078-0432.CCR-14-0889"},{"key":"87456","doi-asserted-by":"crossref","unstructured":"Lv H, Fei Y, Li W. A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. Hematol Oncol. 2022; 40(3):343-355.","DOI":"10.1002\/hon.2994"},{"key":"87457","doi-asserted-by":"crossref","unstructured":"Minson A, Hamad N, Cheah CY. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024; 143(8):673-684.","DOI":"10.1182\/blood.2023021306"},{"key":"87458","doi-asserted-by":"crossref","unstructured":"Jiang VC, Hao D, Jain P. Abstract 771: Multi-omics profiling can predict for relapse and response to brexucabtagene autoleucel CAR T-cell therapy in patients with mantle cell lymphoma. Cancer Res. 2022; 82(12_Supplement):771.","DOI":"10.1158\/1538-7445.AM2022-771"},{"key":"87459","doi-asserted-by":"crossref","unstructured":"Le K, Sun J, Khawaja H. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv. 2021; 5(14):2863-2878.","DOI":"10.1182\/bloodadvances.2020003871"},{"key":"87460","doi-asserted-by":"crossref","unstructured":"Rodrigues JM, Nikkarinen A, Hollander P. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021; 193(3):520-531.","DOI":"10.1111\/bjh.17366"},{"key":"87461","doi-asserted-by":"crossref","unstructured":"Nikkarinen A, Lokhande L, Amini R-M. Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood Adv. 2023; 7(18):5304-5313.","DOI":"10.1182\/bloodadvances.2023010052"},{"key":"87462","doi-asserted-by":"crossref","unstructured":"Ragaini S, Galli A, Genuardi E. Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. Blood Adv. 2025; 9(8):1805-1815.","DOI":"10.1182\/bloodadvances.2024014948"},{"key":"87463","doi-asserted-by":"crossref","unstructured":"Selvin T, Nylund P, Ly A-M. Plasma proteomic profiling identifies prognostic biomarkers in mantle cell lymphoma. Blood. 2024; 144(Supplement 1):1623.","DOI":"10.1182\/blood-2024-209805"},{"key":"87464","doi-asserted-by":"crossref","unstructured":"Lokhande L, Kuci Emruli V, Kolstad A. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. BMC Cancer. 2020; 20(1):1202.","DOI":"10.1186\/s12885-020-07678-4"},{"key":"87465","doi-asserted-by":"crossref","unstructured":"Zhou Y, Chen H, Tao Y, Zhong Q, Shi Y. Minimal residual disease and survival outcomes in patients with mantle cell lymphoma: a systematic review and meta-analysis. J Cancer. 2021; 12(2):553-561.","DOI":"10.7150\/jca.51959"},{"key":"87466","doi-asserted-by":"crossref","unstructured":"Wu S, Blombery P, Westerman D, Tam CS. Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma. Curr Treat Options Oncol. 2023; 24(8):929-947.","DOI":"10.1007\/s11864-023-01102-2"},{"key":"87467","doi-asserted-by":"crossref","unstructured":"Lakhotia R, Melani C, Dunleavy K. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022; 6(8):2667-2680.","DOI":"10.1182\/bloodadvances.2021006397"},{"key":"87468","doi-asserted-by":"crossref","unstructured":"Fenske TS, Wang XV, Till BG. Lack of benefit of autologous hematopoietic cell transplantation (auto-HCT) in mantle cell lymphoma (MCL) patients (pts) in first complete remission (CR) with undetectable minimal residual disease (uMRD): initial report from the ECOG-ACRIN EA4151 phase 3 randomized trial. Blood. 2024; 144(Supplement 2):LBA-6.","DOI":"10.1182\/blood-2024-212973"},{"key":"87469","doi-asserted-by":"crossref","unstructured":"Jerkeman M, Kolstad A, Hutchings M. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. Blood Adv. 2024; 8(2):407-415.","DOI":"10.1182\/bloodadvances.2023011920"},{"key":"87470","doi-asserted-by":"crossref","unstructured":"Hawkes EA, Fletcher R, Wood A. Traverse: a phase 2, open-label, randomized study of acalabrutinib in combination with venetoclax and rituximab in patients with treatment-naive mantle cell lymphoma. Blood. 2023; 142(Supplement 1):3054.","DOI":"10.1182\/blood-2023-174718"},{"key":"87471","doi-asserted-by":"crossref","unstructured":"Jerkeman M, Wader KF, Glimelius I. Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial. Blood. 2024; 144(Supplement 1):747.","DOI":"10.1182\/blood-2024-192939"},{"key":"87472","doi-asserted-by":"crossref","unstructured":"Wang M, Munoz J, Goy A. Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023; 41(3):555-567.","DOI":"10.1200\/JCO.21.02370"},{"key":"87473","doi-asserted-by":"crossref","unstructured":"Wang M, Salek D, Belada D. Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma. J Clin Oncol. 2025; 43(20):2276-2284.","DOI":"10.1002\/hon.70096_846"},{"key":"87474","doi-asserted-by":"crossref","unstructured":"Li P, Yuan J, Ahmed FS. High counts of CD68+ and CD163+ macrophages in mantle cell lymphoma are associated with inferior prognosis. Front Oncol. 2021; 11:701492.","DOI":"10.3389\/fonc.2021.701492"},{"key":"87475","doi-asserted-by":"crossref","unstructured":"Gin\u00e9 E, de la Cruz F, Jim\u00e9nez Ubieto A. Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2022; 40(11):1196-1205.","DOI":"10.1200\/JCO.21.02321"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12980\/79033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12980\/79857","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12980\/79033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:13Z","timestamp":1794046213000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288185","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}